Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.050
-0.010 (-0.49%)
Jan 29, 2026, 10:51 AM EST - Market open
Protalix BioTherapeutics Employees
Protalix BioTherapeutics had 213 employees as of December 31, 2024. The number of employees increased by 5 or 2.40% compared to the previous year.
Employees
213
Change (1Y)
5
Growth (1Y)
2.40%
Revenue / Employee
$290,329
Profits / Employee
$25,324
Market Cap
164.86M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 213 | 5 | 2.40% | 213 | 0 |
| Dec 31, 2023 | 208 | 11 | 5.58% | 208 | 0 |
| Dec 31, 2022 | 197 | -9 | -4.37% | 193 | 4 |
| Dec 31, 2021 | 206 | -1 | -0.48% | 202 | 4 |
| Dec 31, 2020 | 207 | 11 | 5.61% | 207 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Innate Pharma | 174 |
| ProQR Therapeutics | 166 |
| Zentalis Pharmaceuticals | 166 |
| Prelude Therapeutics | 131 |
| Rani Therapeutics Holdings | 106 |
| Nkarta | 105 |
| Acumen Pharmaceuticals | 61 |
| Eledon Pharmaceuticals | 31 |
PLX News
- 24 days ago - Protalix BioTherapeutics Letter to Stockholders - PRNewsWire
- 6 weeks ago - Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement - PRNewsWire
- 2 months ago - Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results - PRNewsWire
- 3 months ago - Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 - PRNewsWire
- 3 months ago - PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 3 months ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU - GlobeNewsWire
- 3 months ago - Why Is Protalix BioTherapeutics Stock Falling On Friday? - Benzinga